{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:37:41Z","timestamp":1783402661618,"version":"3.54.6"},"reference-count":94,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2006,6]]},"DOI":"10.1016\/j.dld.2006.01.020","type":"journal-article","created":{"date-parts":[[2006,5,5]],"date-time":"2006-05-05T06:30:33Z","timestamp":1146810633000},"page":"363-373","source":"Crossref","is-referenced-by-count":39,"title":["Hepatotoxicity and antiretroviral therapy with protease inhibitors: A review"],"prefix":"10.1016","volume":"38","author":[{"given":"R.","family":"Bruno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Sacchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Maiocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Patruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Filice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2006.01.020_bib1","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/S0140-6736(98)03201-2","article-title":"Changing patterns of morbidity and mortality across Europe in patients infected with HIV-1","volume":"352","author":"The EuroSIDA Study Group","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2006.01.020_bib2","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators","volume":"338","author":"Palella","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2006.01.020_bib3","unstructured":"Saag M, Gersten M, Chang Y. Long term virological and immunological effect of the HIV protease inhibitor viracept (nelfinavir mesylate) in combination with zidovudine (AZT) and lamivudine (3TC). Program and Abstracts of the Infectious Disease Society of America 35th Annual Meeting [abstract]."},{"key":"10.1016\/j.dld.2006.01.020_bib4","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJM199709113371101","article-title":"A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic centimeter or less","volume":"337","author":"Hammer","year":"1997","journal-title":"N Engl J Med"},{"issue":"Suppl. A","key":"10.1016\/j.dld.2006.01.020_bib5","first-page":"5157","article-title":"Altered natural history of AIDS-related opportunistic infections in the era of potent combination antiretroviral therapy","volume":"12","author":"Jocobson","year":"1997","journal-title":"Acquir Immune Defic Syndr"},{"key":"10.1016\/j.dld.2006.01.020_bib6","first-page":"176","article-title":"Treatment of HIV infection: tolerability of commonly used antiretroviral agents","volume":"15","author":"Notermans","year":"1996","journal-title":"Drugs Exp"},{"key":"10.1016\/j.dld.2006.01.020_bib7","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1093\/clinids\/14.3.773-a","article-title":"Interactions and toxicities of drugs used in patients with AIDS","volume":"14","author":"Lee","year":"1992","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.dld.2006.01.020_bib8","first-page":"381","article-title":"Discontinuing protease inhibitor therapy for intolerance. Longitudinal study of 309 patients","volume":"28","author":"Piroth","year":"1999","journal-title":"Presse Med"},{"key":"10.1016\/j.dld.2006.01.020_bib9","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1056\/NEJM199804303381808","article-title":"HIV-protease inhibitors","volume":"338","author":"Flexner","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2006.01.020_bib10","first-page":"1256","article-title":"Hepatotoxicity after introduction of highly active antiretroviral therapy","volume":"12","author":"Rodriguez-Rosado","year":"1998","journal-title":"Acquir Immune Defic Syndr"},{"key":"10.1016\/j.dld.2006.01.020_bib11","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/00042560-200110010-00002","article-title":"Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART","volume":"28","author":"d\u2019Arminio Monforte","year":"2001","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.dld.2006.01.020_bib12","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/00042560-200201010-00005","article-title":"Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection","volume":"29","author":"Aceti","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.dld.2006.01.020_bib13","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/00042560-200107010-00017","article-title":"Risk factors for hepatotoxicity in patients treated with highly active antiretroviral therapy","volume":"27","author":"Bonfanti","year":"2001","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.dld.2006.01.020_bib14","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(00)02854-3","article-title":"Adverse effects of antiretroviral therapy","volume":"356","author":"Carr","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2006.01.020_bib15","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/S0140-6736(01)06413-3","article-title":"Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study","volume":"358","author":"Fellay","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2006.01.020_bib16","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1001\/jama.283.19.2526","article-title":"Elevated liver enzymes following initiation of antiretroviral therapy","volume":"283","author":"Sulkowski","year":"2000","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.dld.2006.01.020_bib17","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1086\/317449","article-title":"Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine","volume":"31","author":"Gisolf","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.dld.2006.01.020_bib18","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jama.283.1.74","article-title":"Hepatotoxicity associated with antiviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection","volume":"283","author":"Sulkowski","year":"2000","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.dld.2006.01.020_bib19","first-page":"2277","article-title":"Hepatotoxicity associated with protease inhibitors-based antiretroviral regimens with or without concurrent ritonavir","volume":"18","author":"Sulkowski","year":"2004","journal-title":"Acquir Immune Defic Syndr"},{"key":"10.1016\/j.dld.2006.01.020_bib20","first-page":"1722","article-title":"Acute hepatitis in HIV-infected patients during ritonavir treatment","volume":"12","author":"Arribas","year":"1998","journal-title":"Acquir Immune Defic Syndr"},{"key":"10.1016\/j.dld.2006.01.020_bib21","doi-asserted-by":"crossref","first-page":"670","DOI":"10.7326\/0003-4819-129-8-199810150-00026","article-title":"Hepatotoxicity associated with ritonavir","volume":"129","author":"Picard","year":"1998","journal-title":"Ann Intern Med"},{"issue":"Suppl. 1","key":"10.1016\/j.dld.2006.01.020_bib22","doi-asserted-by":"crossref","first-page":"698a","DOI":"10.1016\/S0270-9139(03)81163-1","article-title":"Hepatotoxicity associated with the antiretroviral therapy (ART) containing protease inhibitors with and without pharmacokinetic boosting by low-dose ritonavir (RTV)","volume":"38","author":"Sulkowski","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2006.01.020_bib23","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1055\/s-2003-39949","article-title":"Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors","volume":"23","author":"Sulkowski","year":"2003","journal-title":"Semin Liver Dis"},{"issue":"Suppl. 2","key":"10.1016\/j.dld.2006.01.020_bib24","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1086\/381444","article-title":"Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors","volume":"38","author":"Sulkowski","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.dld.2006.01.020_bib25","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0140-6736(05)62700-6","article-title":"Severe hepatitis in patients with AIDS and hemophilia B treated with indinavir","volume":"349","author":"Matsuda","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2006.01.020_bib26","first-page":"115","article-title":"Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations, Aquitane cohort, France, 1996\u20131998","volume":"13","author":"Sav\u00e9s","year":"1999","journal-title":"Acquir Immune Defic Syndr"},{"key":"10.1016\/j.dld.2006.01.020_bib27","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1128\/AAC.44.12.3451-3455.2000","article-title":"Hepatitis B or hepatitis C virus infection co-infection and the risk for hepatotoxicity of highly active antiretroviral regimen in human immunodeficiency virus-infected patients","volume":"44","author":"Sav\u00e9s","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.dld.2006.01.020_bib28","first-page":"2895","article-title":"Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection","volume":"14","author":"den Brinker","year":"2000","journal-title":"Acquir Immune Defic Syndr"},{"key":"10.1016\/j.dld.2006.01.020_bib29","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/00042560-200108150-00002","article-title":"Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy","volume":"27","author":"N\u00f9\u0148ez","year":"2001","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.dld.2006.01.020_bib30","first-page":"1261","article-title":"Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy","volume":"15","author":"Martinez","year":"2001","journal-title":"Acquir Immune Defic Syndr"},{"key":"10.1016\/j.dld.2006.01.020_bib31","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1016\/S0002-9343(99)00390-3","article-title":"Hepatitis C virus and human immunodeficiency virus: clinical issues in coinfection","volume":"107","author":"Dieterich","year":"1999","journal-title":"Am J Med"},{"key":"10.1016\/j.dld.2006.01.020_bib32","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0168-8278(97)80274-7","article-title":"Hepatitis B and C in HIV-infected patients. Prevalence and prognostic value","volume":"27","author":"Ockenga","year":"1997","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2006.01.020_bib33","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1093\/clinids\/23.5.1117","article-title":"Reciprocal interactions between human immunodeficiency virus and hepatitis C virus infections","volume":"23","author":"Zylberberg","year":"1996","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.dld.2006.01.020_bib34","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/oxfordjournals.aje.a117636","article-title":"Prognostic factors for all-cause mortality among hemophiliacs infected with human immunodeficiency virus","volume":"142","author":"Diamondstone","year":"1995","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.dld.2006.01.020_bib35","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.7326\/0003-4819-105-3-382","article-title":"Chronic hepatitis B in asymptomatic homosexual men with antibody to the human immunodeficiency virus","volume":"105","author":"Perrillo","year":"1986","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.dld.2006.01.020_bib36","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1055\/s-2007-1007390","article-title":"Interactions of the human immunodeficiency virus and the hepatotropic viruses","volume":"12","author":"McNair","year":"1992","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.dld.2006.01.020_bib37","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/clinids\/18.3.339","article-title":"Clinical aspects of the interactions between human immunodeficiency virus and the hepatotropic viruses","volume":"18","author":"Horvath","year":"1994","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.dld.2006.01.020_bib38","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1468-1293.2004.00232.x","article-title":"Lopinavir\/ritonavir treatment in HIV antiretroviral-experienced patients: evaluation of risk factors for liver enzyme elevation","volume":"5","author":"Meraviglia","year":"2004","journal-title":"HIV Medicine"},{"key":"10.1016\/j.dld.2006.01.020_bib39","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1089\/0889222041524562","article-title":"Liver toxicity of lopinavir-containing regimens in HIV-infected patients with or without hepatitis C coinfection","volume":"7","author":"Gonzalez-Requena","year":"2004","journal-title":"Acquir Immune Defic Syndr Res Hum Retroviruses"},{"key":"10.1016\/j.dld.2006.01.020_bib40","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1086\/341084","article-title":"Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy","volume":"186","author":"Wit","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1016\/j.dld.2006.01.020_bib41","doi-asserted-by":"crossref","first-page":"705","DOI":"10.7326\/0003-4819-125-9-199611010-00001","article-title":"Effects of lamivudine on replication of hepatitis B virus in HIV-infected men","volume":"125","author":"Benhamou","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.dld.2006.01.020_bib42","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc B"},{"key":"10.1016\/j.dld.2006.01.020_bib43","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0140-6736(97)04161-5","article-title":"Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease","volume":"351","author":"Cameron","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2006.01.020_bib44","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJM199709113371102","article-title":"Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy","volume":"337","author":"Gulick","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2006.01.020_bib45","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1056\/NEJM199810293391802","article-title":"A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients","volume":"339","author":"Pialoux","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2006.01.020_bib46","first-page":"148","article-title":"Development of hepatotoxicity in HIV patients switching at least one protease inhibitor","volume":"16","author":"Aceti","year":"2005","journal-title":"Int J Sex Transm Dis Acquir Immune Defic Syndr"},{"key":"10.1016\/j.dld.2006.01.020_bib47","unstructured":"Viracept\u00ae (nelfinavir). Prescribing information\u2014USA. San Diego, CA: Agouron Laboratories; 1999."},{"key":"10.1016\/j.dld.2006.01.020_bib48","unstructured":"Crixivan\u00ae (indinavir sulfate). Prescribing information\u2014USA. Whitehouse Station, NJ: Merck and Co.; 2001."},{"key":"10.1016\/j.dld.2006.01.020_bib49","unstructured":"Reyataz\u00ae (atazanavir sulfate). Prescribing information (USA). Princeton, NJ: Bristol Myers Squibb; 2003."},{"key":"10.1016\/j.dld.2006.01.020_bib50","unstructured":"Norvir\u00ae (ritonavir). Prescribing information (USA). North Chicago, IL: Abbott Laboratories; 1999."},{"key":"10.1016\/j.dld.2006.01.020_bib51","unstructured":"Kaletra\u00ae (lopinavir\/ritonavir) capsules and oral solution. Prescribing information (USA). North Chicago, IL: Abbott Laboratories; 2000."},{"key":"10.1016\/j.dld.2006.01.020_bib52","unstructured":"Fortovase\u00ae (saquinavir). Prescribing information (USA). Nultey, NJ: Roche Laboratories; 1998."},{"key":"10.1016\/j.dld.2006.01.020_bib53","unstructured":"Lexiva\u00ae (fosamprenavir) product information: Lexiva\u2122, fosamprenavir tablets. GlaxoSmithKline, Research Triangle Park, NC."},{"key":"10.1016\/j.dld.2006.01.020_bib54","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.2165\/00003495-200565120-00005","article-title":"Tipranavir. A ritonavir-boosted protease inhibitor","volume":"65","author":"Croom","year":"2005","journal-title":"Drugs"},{"key":"10.1016\/j.dld.2006.01.020_bib55","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1128\/AAC.48.5.1904-1907.2004","article-title":"Pharmacokinetics of indinavir combined with low-dose ritonavir in human immunodeficiency virus type 1-infected children","volume":"48","author":"Bergshoeff","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.dld.2006.01.020_bib56","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1128\/AAC.48.2.430-436.2004","article-title":"Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women","volume":"48","author":"Acosta","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.dld.2006.01.020_bib57","unstructured":"Hendrix CW, Fiske WD, Fuchs EJ. Pharmacokinetics of the triple combination of saquinavir, ritonavir, and efavirenz in HIV-positive patients. Presented at the 7th Conference on Retroviruses and Opportunistic Infections [abstract 79]."},{"key":"10.1016\/j.dld.2006.01.020_bib58","first-page":"F23","article-title":"Virologic responses to a ritonavir\u2013saquinavir-containing regimen in patients who had previously failed nelfinavir","volume":"13","author":"Tebas","year":"1999","journal-title":"Acquir Immune Defic Syndr"},{"key":"10.1016\/j.dld.2006.01.020_bib59","first-page":"2795","article-title":"Switch from indinavir to ritonavir\u2013indinavir regimen in patients treated with highly active antiretroviral therapy co-infected with hepatitis C is not associated with alteration of liver function tests","volume":"14","author":"Vora","year":"2000","journal-title":"Acquir Immune Defic Syndr"},{"key":"10.1016\/j.dld.2006.01.020_bib60","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMoa012354","article-title":"Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection","volume":"346","author":"Walmsley","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2006.01.020_bib61","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.antiviral.2003.12.002","article-title":"Lopinavir\/ritonavir vs. indinavir\/ritonavir in antiretroviral naive HIV-infected patients: immunovirological outcome and side effects","volume":"62","author":"Bongiovanni","year":"2004","journal-title":"Antiviral Res"},{"key":"10.1016\/j.dld.2006.01.020_bib62","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1086\/375233","article-title":"A review of low-dose ritonavir in protease inhibitor combination therapy","volume":"36","author":"Cooper","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.dld.2006.01.020_bib63","unstructured":"Sherman KE, Shire NJ, Cernohous P. Evaluation of HCV RNA and liver injury in HCV\/HIV coinfected patients initiating lopinavir or nelfinavir-based therapy. Presented at the 11th Conference on Retrovirus and Opportunistic Infections [poster 811]."},{"key":"10.1016\/j.dld.2006.01.020_bib64","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1097\/00126334-200406010-00005","article-title":"Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir","volume":"36","author":"Wood","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.dld.2006.01.020_bib65","first-page":"1610","article-title":"Acute hepatic cytolysis in an HIV-infected patient taking atazanavir","volume":"18","author":"Eholie","year":"2004","journal-title":"Acquir Immune Defic Syndr"},{"key":"10.1016\/j.dld.2006.01.020_bib66","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1021\/jm9802158","article-title":"Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class","volume":"41","author":"Turner","year":"1998","journal-title":"J Med Chem"},{"key":"10.1016\/j.dld.2006.01.020_bib67","first-page":"101","article-title":"In-vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitors","volume":"14","author":"Back","year":"2000","journal-title":"Acquir Immune Defic Syndr"},{"key":"10.1016\/j.dld.2006.01.020_bib68","unstructured":"Kohlbrenner V, Gathe J, Pierone G. Tipranavir\/ritonavir (TPV\/R) demonstrates potent efficacy in multiple protease inhibitor (PI) experienced patients at 24 weeks: BI 1182.52. Program and abstracts of the 9th European AIDS Conference (EACS), 1st EACS Resistance & Pharmacology Workshop. Warsaw, Poland; 25\u201329 October; 2003 [abstract 7.2\/2]."},{"issue":"Suppl. 2","key":"10.1016\/j.dld.2006.01.020_bib69","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1086\/381448","article-title":"Pitfalls of assessing hepatotoxicity in trials and observational cohorts","volume":"38","author":"Sabin","year":"2004","journal-title":"CID"},{"key":"10.1016\/j.dld.2006.01.020_bib70","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0140-6736(05)62700-6","article-title":"Severe hepatitis in three AIDS patients treated with indinavir","volume":"349","author":"Brau","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2006.01.020_bib71","first-page":"53","article-title":"Indinavir-associated hepatitis in patients with advanced HIV infection","volume":"9","author":"Vergis","year":"1998","journal-title":"Int J Sex Transm Dis Acquir Immune Defic Syndr"},{"key":"10.1016\/j.dld.2006.01.020_bib72","first-page":"116","article-title":"Enhancement of hepatitis C virus replication and liver damage in HIV coinfected patients on antiretroviral combination therapy","volume":"12","author":"Vento","year":"1998","journal-title":"Acquir Immune Defic Syndr"},{"key":"10.1016\/j.dld.2006.01.020_bib73","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(05)62892-9","article-title":"Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor","volume":"349","author":"Carr","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2006.01.020_bib74","first-page":"2289","article-title":"Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with protease inhibitors: an immune restoration disease?","volume":"12","author":"John","year":"1998","journal-title":"Acquir Immune Defic Syndr"},{"key":"10.1016\/j.dld.2006.01.020_bib75","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S0140-6736(05)78279-9","article-title":"Effects of HAART on natural history of AIDS-related opportunistic disorders","volume":"351","author":"Sepkowitz","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2006.01.020_bib76","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1089\/08892220050075264","article-title":"Enhancement of hepatitis C virus replication and liver damage in HIV coinfected patients on antiretroviral combination therapy: differences between complete and partial virologic responders","volume":"16","author":"Gavazzi","year":"2000","journal-title":"Acquir Immune Defic Syndr Res Hum Retroviruses"},{"key":"10.1016\/j.dld.2006.01.020_bib77","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1086\/517808","article-title":"Impact of antiretroviral treatment with HIV protease inhibitors in hepatitis C viremia in patients coinfected with HIV","volume":"177","author":"Rutschmann","year":"1998","journal-title":"J Infect Dis"},{"key":"10.1016\/j.dld.2006.01.020_bib78","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/hep.510300409","article-title":"Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients","volume":"30","author":"Benhamou","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2006.01.020_bib79","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/BF02088247","article-title":"Effect of human immunodeficiency virus infection on hepatitis C virus infection in hemophilisac","volume":"41","author":"Ghany","year":"1996","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.dld.2006.01.020_bib80","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0923-2516(96)82284-9","article-title":"Role of endogenous interferon in hepatits C virus (HCV) infection and in coinfection by HIV and HCV","volume":"147","author":"Cribier","year":"1996","journal-title":"Res Virol"},{"key":"10.1016\/j.dld.2006.01.020_bib81","first-page":"1995","article-title":"Differential effect of ritonavir and indinavir on immune response to hepatitis C virus in HIV-1 infected patients","volume":"13","author":"Michelet","year":"1999","journal-title":"Acquir Immune Defic Syndr"},{"key":"10.1016\/j.dld.2006.01.020_bib82","first-page":"95","article-title":"Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir","volume":"11","author":"Lorenzi","year":"1997","journal-title":"Acquir Immune Defic Syndr"},{"key":"10.1016\/j.dld.2006.01.020_bib83","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.7326\/0003-4819-124-12-199606150-00003","article-title":"The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients","volume":"124","author":"Schapiro","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.dld.2006.01.020_bib84","first-page":"F111","article-title":"The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy","volume":"12","author":"Hoetelmans","year":"1998","journal-title":"Acquir Immune Defic Syndr"},{"key":"10.1016\/j.dld.2006.01.020_bib85","unstructured":"Acosta EP, Havlir DH, Richman DD. Pharmacodynamics (PD) of indinavir (IDV) in protease-na\u00efve HIV-infected patients receiving ZDV and 3TC. 7th Conference on Retroviruses and Opportunistic Infections [abstract 455]."},{"key":"10.1016\/j.dld.2006.01.020_bib86","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1592\/phco.19.9.708.31544","article-title":"Indinavir concentrations and antiviral effect","volume":"19","author":"Acosta","year":"1999","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.dld.2006.01.020_bib87","first-page":"2083","article-title":"The relationship between ritonavir plasma levels and side-effects: implications for therapeutic drug monitoring","volume":"13","author":"Gatti","year":"1999","journal-title":"Acquir Immune Defic Syndr"},{"key":"10.1016\/j.dld.2006.01.020_bib88","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1046\/j.1365-2125.1999.00919.x","article-title":"Pharmacokinetic variability and strategy for therapeutic drug monitoring of saquinavir (SQV) in HIV infected individuals","volume":"47","author":"Regazzi","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.dld.2006.01.020_bib89","unstructured":"Arribas J, Pulido F, Peng JZ. Evaluation of the multiple-dose pharmacokinetics of lopinavir\/ritonavir (LPV\/R) in HIV and HCV coinfected subjects with mild or moderate hepatic insufficiency. 9th European AIDS Conference (EACS). Warsaw, Poland; 2003 [abstract F2\/6]."},{"key":"10.1016\/j.dld.2006.01.020_bib90","unstructured":"Bossi P, Peytavin G, Lamotte C. High indinavir plasma concentartion in HIV-1 patients co-infecetd with hepatitis B or C virus receiving indinavir and ritonavir low dosages: a GENOPHAR substudy. 10th Congress on Retroviruses and Opportunistic Infections [abstract 546]."},{"key":"10.1016\/j.dld.2006.01.020_bib91","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1128\/AAC.49.2.643-649.2005","article-title":"Clinical pharmacokinetics of nelfinavir and its metabolite M8 in human immunodeficiency virus (HIV)-positive and HIV-Hepatitis C virus-coinfected subjects","author":"Regazzi","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.dld.2006.01.020_bib92","first-page":"59","article-title":"Toxicity and drug exposure in a quadruple drug regimen in HIV-1 infected patients participating in the ADAM study","volume":"14","author":"Reijers","year":"2000","journal-title":"Acquir Immune Defic Syndr"},{"key":"10.1016\/j.dld.2006.01.020_bib93","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.2165\/00003495-200565160-00010","article-title":"Atazanavir. A review of its use in the management of HIV infection","volume":"65","author":"Swainston Harrison","year":"2005","journal-title":"Drugs"},{"key":"10.1016\/j.dld.2006.01.020_bib94","doi-asserted-by":"crossref","first-page":"633","DOI":"10.2165\/00003495-200565050-00005","article-title":"Amprenavir or fosamprenavir plus ritonavir in HIV Infection. Pharmacology, efficacy and tolerability profile","volume":"65","author":"Arvieux","year":"2005","journal-title":"Drugs"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865806000211?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865806000211?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T20:41:17Z","timestamp":1736368877000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865806000211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6]]},"references-count":94,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["S1590865806000211"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2006.01.020","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2006,6]]}}}